- Home
- PERF vs CMPX Comparison
PERF vs CMPX Comparison
Compare PERF & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PERF
- CMPX
- Stock Information
- Founded
- PERF 2015
- CMPX 2014
- Country
- PERF Taiwan
- CMPX United States
- Employees
- PERF N/A
- CMPX N/A
- Industry
- PERF Computer Software: Prepackaged Software
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- PERF Technology
- CMPX Health Care
- Exchange
- PERF Nasdaq
- CMPX Nasdaq
- Market Cap
- PERF 197.6M
- CMPX 206.3M
- IPO Year
- PERF N/A
- CMPX N/A
- Fundamental
- Price
- PERF $1.85
- CMPX $1.49
- Analyst Decision
- PERF Buy
- CMPX Strong Buy
- Analyst Count
- PERF 2
- CMPX 3
- Target Price
- PERF $4.00
- CMPX $7.67
- AVG Volume (30 Days)
- PERF 59.2K
- CMPX 528.2K
- Earning Date
- PERF 10-29-2024
- CMPX 11-12-2024
- Dividend Yield
- PERF N/A
- CMPX N/A
- EPS Growth
- PERF N/A
- CMPX N/A
- EPS
- PERF 0.05
- CMPX N/A
- Revenue
- PERF $58,445,000.00
- CMPX $850,000.00
- Revenue This Year
- PERF $15.77
- CMPX N/A
- Revenue Next Year
- PERF $13.89
- CMPX $747.71
- P/E Ratio
- PERF $36.84
- CMPX N/A
- Revenue Growth
- PERF 15.84
- CMPX N/A
- 52 Week Low
- PERF $1.70
- CMPX $0.77
- 52 Week High
- PERF $3.77
- CMPX $2.34
- Technical
- Relative Strength Index (RSI)
- PERF 46.80
- CMPX 42.24
- Support Level
- PERF $1.78
- CMPX $1.34
- Resistance Level
- PERF $1.92
- CMPX $1.46
- Average True Range (ATR)
- PERF 0.08
- CMPX 0.14
- MACD
- PERF 0.00
- CMPX -0.03
- Stochastic Oscillator
- PERF 45.63
- CMPX 30.14
About PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions that are ultra-personalized, interactive and engaging, from online to in-store through beauty mirrors. Geographically, the company has a presence in the United States, France, Japan and Others.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.